A Validated Model for Identifying Patients Unlikely to Benefit From the 21-Gene Recurrence Score Assay

Predicting recurrence risk and chemotherapy benefit in early-stage breast cancer is challenging. The Oncotype DX gene assay is often used. Using a database of 221 patients a simple 2-rule model was developed and validated on an independent group of 319 patients. The model categorizes patients unlike...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Breast Cancer
Main Authors: Gage, Michele M., Rosman, Martin, Mylander, W. Charles, Giblin, Erica, Kim, Hyun-seok, Cope, Leslie, Umbricht, Christopher, Wolff, Antonio C., Tafra, Lorraine
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4847530/
https://ncbi.nlm.nih.gov/pubmed/26072275
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clbc.2015.04.006
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados